Mumbai: India’s immunization plan against Covid-19 can be immediately supported by the launch of a single-dose sputnik lamp produced locally in September.
PANACEA BIOTEC, which previously partnered before Direct Russian investment funds (RDIF), has submitted documents to find authorization of emergency use to Indian drug regulators recently, said the source to TOI.
Vaccines, which will be available in a limited amount initially, are expected to be valued around Rs 750.
Until now, the immunization program has used the import of two doses of Sputnik V, launched by Dr.
Reddy’s, RDIF-based exclusive distribution partners based in Hyderabad.
for India.
The lack of supply of two vutnic doses v can be completed as early as the end of the month, with a sleek rock rampdy, the source added.
The full launch of the Sputnik V vaccine was detained and therefore was left behind, because the import of Russia was affected in June.
About five doses of Lakh component 2 Sputnik v vaccines, which have been imported, can be launched in India soon.
“ We also work closely with our partners in India for making readiness.
We hope that local-produced doses tend to be available from the September-October “period, said Spokesman Dr.
Reddy.
Sputnik Light, which was developed by Russia’s Gamaleya Institute and was supported by RDIF, accepting authorization of emergency use in Russia in May.
This is considered by experts because it is more ‘suitable’, given the task to vaccinate the large population even as a possible third wave weaving tool.
Light Jab Sputnik has shown almost 80% efficacy, according to data analyzed 28 days after injection was given in experiments in Russia, RDIF statement said.
Previously in July, Panacea Biotec had announced the receipt of manufacturing licenses to produce Sputnik V vaccines in Baddi factories at Himachal Pradesh.
The batch produced in Baddi has successfully passed the examination for good quality parameters at the Gamaleya Center in Russia and in the Central Medicine Laboratory, Kasauli (Himachal Pradesh).
Panacea will produce 100 million doses every year from vaccines that will be distributed by Dr.
Reddy’s.
Also, the expert panel under the Ministry of Health allows Dr.
Reddy to submit Russian safety data for vaccine approval in India.
“Furthermore, the SEC (the Subject Expert Committee) also observed that considering the safety and immunogenicity data that had been produced by Dr.
Reddy in India in the first dose component of Sputnik V (in other words, lightweight sputnik), no need for a phase III court separate from the light Sputnik in India, “he added.
It is considering that the fact that Sputnik Light is the first dose component of Sputnik V.
It also recommends that Dr.
Reddy must submit the safety, immunogenicity, and efficacy data from phase III clinical trials from Sputnik V in Russia to Russia to the consideration of the marketing of sputnik light marketing in India.